At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02257 SIRNAOMICS-B
Closed 02-02 16:05:00
7.730
-0.020
-0.26%
High7.760
Low7.340
Vol330.85K
Open7.760
D1 Closing7.750
Amplitude5.42%
Mkt Cap827.11M
Tradable Cap827.11M
Total Shares107.00M
T/O2.49M
T/O Rate0.31%
Tradable Shares107.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SIRNAOMICS-B (02257) Completes Phase I Trial of Investigational Drug STP707 and Submits Clinical Study Report to FDA
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a multi-targeted siRNA therapeutic advancing clinical development across two oncology indications: squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Its STP707 is an intravenous siRNA therapeutic being evaluated in phase I clinical trial for multiple solid tumors, including colorectal, pancreatic, liver, and metastatic melanoma cancers. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.